Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of apatinib in advanced malignant solid tumors
ChiCTR1800017375Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC) and 7 more, sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoint: progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)bronchial carcinomaovarian cancer
Beyond the preview
Go deeper on ChiCTR1800017375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017375.